Clinical Trial Update: Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R) [Phase 2]

View source ↗

Summary

Phase 2 trial of Proteinase 3 PR1 peptide with Montanide adjuvant, GM-CSF, and PEG-Intron in leukemia was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• GM-CSF (granulocyte-macrophage colony-stimulating factor)
• Montanide ISA-51 VG (Montanide ISA-51 VG)
• PEG Intron (pegylated interferon alfa-2b)
• Proteinase 3 PR1 peptide (proteinase 3 PR1 peptide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2014-04-30